Jasper Therapeutics JSPR 深 沪
交易中 10-14 10:13:09 美东时间
0.503
+0.007
+1.49%
华盛通- 最 高0.508
- 今 开0.5012
- 成交量 2.68万股
- 最 低 0.4949
- 昨 收 0.4956
- 总市值 1673.71万
- 52周最高 2.52
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 0.3151
- 委 比 -42.86%
- 总股本 3327.46万
- 历史最高 188.80
- 量 比 1.42
- 振 幅 2.64%
- 历史最低 0.3151
- 每 手 1
- 风险率 0.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jasper Therapeutics Launches Tender Offer to Retire Warrants
Jasper Therapeutics ( ($JSPR) ) has issued an update. On October 7, 2026, Jaspe...
10-07 20:28
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Jasper Therapeutics, Inc. has commenced an offer to purchase all outstanding warrants issued in its September 2025 public offering at a price of $0.324 per warrant. The purpose is to reduce potential dilution and provide clarity on the company's capital structure. The offer will expire on November 6, 2026, with un-tendered warrants expiring on March 18, 2030. Jasper is a clinical-stage biotech company developing therapies for immune-mediated dise...
10-07 12:00
Jasper Therapeutics Appoints Jeet Mahal As Interim Principal Financial Officer Effective October 9, 2026; Herb Cross Resigns As CFO Effective October 9, 2026
On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. (the "Company") in order to pursue other professional endeavors. ...
09-29 04:48
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Jasper Therapeutics announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, in New York. Management will engage in a fireside chat, which will be live-streamed and archived on the company's website. Jasper, a clinical-stage biotech company, is developing innovative therapies for immune-mediated diseases, including KP-104, briquilimab, and KP-701.
09-09 12:00
Jasper Therapeutics Q2 EPS $(0.10) Beats $(0.26) Estimate
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.26) by 61.54 percent. This is a 94.25 percent increase over losses of $(1.74) per share from the same period last year.
08-15 04:27
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Piper Sandler Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $2
Piper Sandler analyst Biren Amin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Overweight rating and announces Price Target of $2.
08-12 17:21
Jasper Therapeutics Completes The Acquisition Of Kira Pharmaceuticals; Announces $132M Private Placement Of Convertible Preferred Stock; Combined Company Operations Expected To Be Funded Through Second Half Of 2028
Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper" or the "Company"), today announced that Jasper has completed the acquisition of Kira Pharmaceuticals ("Kira"), a former Cayman limited company that was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock t...
07-17 05:18
Jasper Therapeutics Received Notice Of Non-Compliance With Nasdaq Minimum Bid Requirements On June 3
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001788028/000121390026066782/ea0294010-8k_jasper.htm
06-10 04:10
Jasper Therapeutics shares are trading lower. The company announced its Board has decided to initiate a comprehensive review of strategic alternatives to maximize shareholder value.
Jasper Therapeutics shares are trading lower. The company announced its Board h...
06-02 03:50
